China SXT Pharmaceuticals (SXTC) Retained Earnings (2018 - 2026)

China SXT Pharmaceuticals (SXTC) has reported Retained Earnings for 9 consecutive years, with -$34.2 million the latest figure, recorded in Q1 2026.

• Quarterly Retained Earnings fell 22.15% year-over-year to -$34.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$34.2 million (down 22.15% YoY) and the FY2026 annual result came in at -$34.2 million, down 22.15% from the prior year.
• Retained Earnings held at -$34.2 million in Q1 2026 per SXTC's latest filing, from -$34.4 million in the prior quarter.
• Over the last five years, Retained Earnings for SXTC reached as high as $35.9 million in Q3 2023 and fell as low as -$34.4 million in Q3 2025.
• A 5-year average of -$1.1 million and a median of -$21.6 million in 2023 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2022 — Retained Earnings grew 25.2% — and 2025, when it sank 202.98%.
• Year by year, Retained Earnings stood at $32.6 million in 2022, then climbed by 10.4% to $35.9 million in 2023, then decreased by 7.12% to $33.4 million in 2024, then plunged by 202.98% to -$34.4 million in 2025, then gained by 0.48% to -$34.2 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$34.2 million, -$34.4 million, and -$28.0 million for Q1 2026, Q3 2025, and Q1 2025 respectively.